Indeed, the identification of RBD-specific clonotypes with germline BCR configurations and autoreactive targeting confirms that autoreactivity and antiviral targeting can be generated simultaneously in the robust EF responses identified in severe COVID-19. The gene discussed is BCR; the disease is COVID-19.